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Abstract. Prostratin, a phorbol ester natural plant compound,
has been demonstrated to exert an anti‑retroviral effect
through activation of latent cluster of differentiation (CD)4+T
lymphocytes and inhibition of viral entry into the cell through
downregulation of chemokine receptor type 4 (CXCR4)
expression. However, the potential effect of prostratin on
cancer is yet to be defined. As CXCR4 is well known to induce
cancer migration, it was hypothesized that prostratin induces
an anti‑cancer effect through inhibition of CXCR4 expression.
The authors previously demonstrated that high stimulating
conditions (sub‑minimal IL‑17, 0.1 ng/ml, synergized with
high salt, Δ0.05 M NaCl) promote breast cancer cell proliferation and CXCR4 expression through upregulation of
salt‑inducible kinase (SIK)‑3. The present study demonstrated
that prostratin selectively exerted increased cytotoxicity (IC50
of 7 µM) when breast cancer cells were cultured in high
stimulating conditions, compared with regular basal culture
conditions (IC50 of 35 µM). Furthermore, the cytotoxic potential of prostratin was increased seven‑fold in the four breast
cancer cell lines (MCF‑7, MDA‑MB‑231, BT‑20 and AU‑565)
compared with the non‑malignant MCF10A breast epithelial
cell line. This suggested that prostratin specifically targets
cancer cells over normal cells. Mechanistic studies revealed
that prostratin inhibited CXCR4 expression in breast cancer
cells through downregulation of SIK3 expression. Overall,
the data suggest that prostratin is a novel drug target for the
pro‑oncogenic factor SIK3. These studies could form a basis
for further research to evaluate the anticancer effect of prostratin in a combinatorial chemotherapeutic regimen.
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Introduction
Chronic inflammation is a well‑established hallmark of cancer
proliferation (1). The cellular stress caused by inflammation
induces release of cytokine and chemokine factors which
induce tumor progression and metastasis (2). Several agents
have been suggested to induce chronic inflammation (3).
Recent evidence from our lab have demonstrated that breast
cancer cells cultured under high salt conditions (Δ0.05 M
NaCl, 50% above basal culture conditions) were able to upregulate reactive nitrogen species (4,5). Importantly, sodium‑MRI
studies in breast cancer patients have demonstrated an
increased sodium content, of up to 63% above the surrounding
soft tissue, in the breast tumors (6,7). These support a notion
that high salt exerts an effector role on tumor progression,
either working individually or synergistically to enhance an
inflammatory tumor microenvironment. Phospho‑proteomic
based studies from our laboratory have demonstrated that high
salt (Δ0.05 M) synergized with sub‑minimal stimulation of
IL‑17 (0.1 ng/ml) induced upregulation of SIK‑3, salt inducible kinase‑3, a serine‑specific protein kinase in breast cancer
cells (8). Mechanistic studies have demonstrated that SIK3
played a crucial role in induction of G1/S‑phase release of cell
cycle, along with enhanced expression of metastasis specific
chemokine CXCR4 in breast cancer cells. Histone deacetylase (HDAC4) is a well‑documented downstream target of
SIK3 (9). The phosophorylation of HDAC4 is known to induce
cell proliferation and malignancy. SIK3 induced phosphorylation of HDAC4. Further, equimolar treatment with mannitol or
sucrose did not exert similar pro‑cancer effect, thus strongly
suggesting that high sodium chloride specifically induces a
pro‑cancer effect (8).
Natural plant product prostratin (12‑deoxyphorbol
13‑acetate) is widely studied for it's activation of latent
T‑cells infected with HIV. Prostratin is identified as a pharmacologically active ingredient in the Samoan medicinal
plant Homolanthus nutans (10). Molecular studies have
demonstrated that prostratin exerts its anti‑HIV effect through
activation of protein kinase C (11). Importantly, prostratin
is shown to induce downregulation of chemokine receptor
CXCR4 in CD4+T lymphocytes there by preventing the entry
of HIV‑1 virus into lymphocytes (12).
The C‑X‑C chemokine receptor type 4 (CXCR4), belongs
to the superfamily of the heterotrimeric G protein‑coupled
receptors and is expressed on the cell surface of various types
of metastatic breast cancer cells. It is important to note that the
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role of CXCR4 in cell proliferation and metastasis was obtained
from the elegant studies performed by Dewan et al (13), when
less invasive MCF‑7 breast cancer lines with low expression
of CXCR4 formed much smaller tumor mass the SCID‑mice
compared to those larger tumor size the highly invasive
MDA‑MB‑231 cell line with high expression of CXCR4. This
is further corroborated with the studies by Lapteva et al (14),
where in, siRNA based knock‑down of CXCR4 in breast cancer
cells tumors cells decrease the tumor growth and size in the
murine breast cancer models. Taken together, as prostratin has
shown to mediate CXCR4 downregulation in HIV infected
cells and CXCR4 is important for cancer proliferation, in our
current communication, we studied the anti‑cancer effect of
prostratin through modulation of CXCR4 expression on cancer
cells.
Materials and methods
Cell cultures and plasmids. Five breast tissue related cell lines
were used in our studies, of these, four breast cancer cells
(MCF7, MDA‑MB‑231, BT20, AU565) and one normalized
breast epithelial cell line (MCF10A) were utilized and obtained
from the American Type Culture Collection (ATCC, Manassas,
VA, USA). The cells were cultured in cell basal essential media
(RPMI-1640 media; Thermo Fisher Scientific, Inc., Waltham,
MA, USA) along with the media supplements such as fetal
bovine serum, penicillin/streptomycin, fungizone, HEPES and
glutamine, as recommended by the manufacturer and as previously described (4,15). Cell lines were frozen in liquid vapor
nitrogen at ‑130˚C until use. Upon thawing, cells were maintained in 5% CO2 incubator in sterile essential media at 37˚C.
For salt and interleukin‑17 treatment conditions, cell culture
media was supplemented with 0.05 M NaCl (Sigma‑Aldrich;
Merck KGaA, Darmstadt, Germany) and 0.1 ng/ml IL‑17
(Thermo Fisher Scientific, Inc.). We have previously performed
a dose‑response for salt (0‑0.1 M NaCl) and IL‑17 (0‑1,000 ng/
ml) and found‑out that 0.05 M NaCl provided highest cell
proliferation (4,5) and 0.1 ng/ml of IL‑17 induced sub‑effective
inflammatory cytokine response (4,16). All chemicals unless
mentioned were obtained either from Sigma‑Aldrich; Merck
KGaA (Darmstadt, Germany) or Thermo Fisher Scientific, Inc.
For siRNA knock down of SIK3 we have used the following
two siRNA sequences: SIK3‑siRNA‑1: 5'‑GUGCAGAGUGUU
GGAGUCC‑3'; scramble SIK3‑siRNA‑1: 5'‑UGGAGGCGA
GUCAGUUUGC‑3'.
Western blot/immunoprecipitation. Total proteins were
extracted from cells with lysis buffer for western blot analysis
as previously described (17,18). Total proteins were separated
on a 4‑12% sodium dodecyl sulfate‑polyacrylamide gradient gel
and transferred onto a nitrocellulose membrane. The membranes
were blocked overnight at 4˚C in Tris‑buffered saline with 0.05%
Tween 20 (5% nonfat milk in 10 mM Tris‑HCl‑100 mM NaCl‑0.
1% Tween 20, pH 7.4). The membranes were incubated first with
Abs specific for total and phosphorylated forms at room temperature with primary Abs diluted 1 in 1,000 in blocking buffer for
2 h, and then with a horseradish peroxide‑conjugated secondary
IgG mAb diluted 1 in 5,000 for 1 h. All primary and secondary
Abs were obtained from Santa Cruz Biotechnology, Inc., (Dallas,
TX, USA). All primary and secondary antibodies for western
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blot and immunoprecipitation were obtained from either Abcam
(Cambridge, MA, USA) or Santa Cruz Biotechnology, Inc. The
following specific primary antibodies to SIK3 (ab211424; Abcam)
GADPH (sc‑47724), Actin (sc‑8432), HDAC4 (sc‑46672; all
from Santa Cruz Biotechnology, Inc.), pHDAC4‑S632 (ab39408;
Abcam). The membrane was developed using the chemiluminescence kit (EMD Millipore, Billerica, MA, USA) and analyzed
on using Universal Hood II by Bio-Rad Laboratories, Inc.,
(Hercules, CA, USA). Morphometric analysis was done using
the software provided by the company.
For SIK3 immunoprecipitation, the cultured cells were
washed with cold PBS, and lysed for 30 min on ice with 0.5 ml
of lysis buffer as previously mentioned (16,19). To the lysis
buffer 0.5 ml of dilution buffer was added and centrifuged
at 17,000 x g for 30 min. The supernatant was transferred
and 1 µg normal chicken IgY (ab97135; Abcam) or chicken
anti‑SIK3 were added. After overnight incubation at 4˚C, 30 µl
carbolink beads (Pierce, Thermo Fisher Scientific, Inc.) were
added to lysates and incubated for 2 h for chicken antibody
immunoprecipitation as per manufacturer's protocol. Beads
were washed with 700 µl of wash ice cold buffer four times,
3 min each time followed by centrifugation at 1,800 x g for
3 min at 4˚C. Beads were then washed with cold PBS and bound
proteins were eluted by boiling with 30 µl of 2X SDS buffer
for 10 min. Proteins were subjected to SDS‑PAGE (4‑12% gel)
and immunoblotting. Phosphorylation of SIK3 were detected
with a mouse monoclonal phospho‑serine antibody (sc‑81514;
Santa Cruz Biotechnology, Inc.).
Reverse transcription‑quantitative polymerase chain reac‑
tion (RT‑qPCR). Expression profiles of genes at mRNA level
in the breast cancer cell lines were analyzed using the TaqMan
FAM‑labeled RT‑PCR primers for SIK3 (Hs00228549_m1),
GADPH (Hs402869), and Actin (Hs4333762T), obtained
from Applied Biosystems; Thermo Fisher Scientific, Inc.
as per the manufacturer's recommendation. Briefly, total
RNA was extracted from 10 6 cells using TRIzol reagent
(Sigma‑Aldrich; Merck KGaA) and analyzed as mentioned
previously (20‑22). RNA samples were quantified by absorbance at 260 nm. The RNA was reverse‑transcribed and
RT‑PCR (real time PCR) was performed in a final reaction
volume of 20 µl using CFX96 (Bio-Rad Laboratories, Inc.).
Each sample was analyzed in triplicate. Cycling conditions
consisted of an initial denaturation of 95˚C for 15 min,
followed by 40 cycles of 95˚C for 30 sec, followed by 61˚C
for 1 min.
Cell proliferation assay. Cell viability was measured by
trypan blue dye exclusion (Sigma‑Aldrich; Merck KGaA) and
MTT assay (Thermo Fisher Scientific, Inc.) as previously
described (4). Briefly, the viability of breast cancer cells was
assessed by measuring mitochondrial activity using MTT
(4,5‑dimethylthiazol‑2‑yl) 2,5‑diphenyltetrazolium bromide)
assay. For various treatment conditions the cancer cells were
plated in 96 well plate for 48‑72 h, the cells were incubated with
5 mg/ml MTT in PBS for 2 h, latter lysed with manufacturer
provided reagents. Detection at 570 nm was performed using
EMax Plus spectrophotometer and data analysis was carried
out using software provided by the manufacturer (Molecular
Devices, LLC, Sunnyvale, CA, USA). Viability was calculated
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Figure 1. Prostratin induces cytotoxicity in breast cancer cells. (A) Dose titration of prostratin (0 to 200 µM) on MCF‑7 cells; (filled squares) represent cells
cultured under basal conditions; (open circles) represent cells cultured under high salt stimulating conditions (Δ0.05 M NaCl+0.1 ng/ml IL‑17). (B) Dose titration was performed on the five breast cell lines, of which four (MCF‑7, MDA‑MB‑231, BT‑20, AU‑565) are breast cancer lines and MCF‑10 A is non‑malignant
breast epithelial cell line. Data were curve fit using the equation provided in methods section. IC50 and Cmax were obtained are presented above. One‑way
ANOVA analysis was performed for statistical analysis to determine the statistical significance of IC50 and Cmax for comparison between unstimulated and
stimulated groups; significance taken at P<0.05, represented by astericks (*).

as percentage compared to untreated cells. Drug dose‑reponse
parameters were obtained using the following equation:
y=100 ‑ [A*x/(K + x)]
where, y is cell viability (%); x is prostratin concentration (µM);
A is defined as the maximum cell viability following highest
drug treatment, this data will be reported as maximal prostratin
cytoxicity (Cmax), as represented as (100‑A); K is defined as the
concentration of prostratin at which there is 50% of Cmax loss
of cell viability and is reported as IC50. While Cmax and IC50
are obtained by best curve fit (with R‑square value >0.95), the
highest drug treatment within the limitation of our experimental
data collection is shown at approximately three fold concentration above IC50. The best curve fit was analyzed using Microcal
Origin v7.0 (Microcal Software, Westborough, MA, USA).
HDAC4 assay kit. The HDAC4 activity analysis (Epigentek,
Farmingdale, NY, USA) was performed on the nuclear fragments of the cell lysates under various assay conditions as per
manufacturer's instructions. Calorimetry detection at 450 nm
was performed using EMax Plus spectrophotometer and
data analysis was carried out using software provided by the
manufacturer (Molecular Devices, LLC). The data analysis
was performed based on a standard curve obtained using the
positive controls provided by the manufacturer as previously
described.
CXCR4 membrane expression assay. CXCR4 expression was
analyzed by flow cytometry as previously described (23). Briefly,
the CXCR4 protein was labeled by mouse anti‑CXCR4 primary
antibody (Santa Cruz Biotechnology, Inc.) in 1:20 dilution to a
200 µl final volume of cells (1x105 cells/ml). Antibodies used
for flow cytometry included anti‑mouse‑FITC (BD Biosciences,
San Jose, CA, USA), and the samples were latter analyzed using
a FACS Calibur/LSRII flow cytometer (BD Biosciences). Data
were analyzed using BD FACSDiva software. Gates were set
according to isotype controls.
Statistical analysis. All data were presented as mean
values ± SEM from four independent experiments. Student
t‑test performed for statistical analysis. P<0.05 was considered
to indicate a statistically significant difference. All data
analysis were performed using Origin 6 software (Origin

Labs, Northampton, MA, USA) or SPSS software v21 (IBM
Corp., Armonk, NY, USA).
Results
Enhanced cytotoxic effect of prostratin on breast cancer cells
in the presence of high salt environment. To study the effect
on prostratin on breast cancer cells in the presence on high
salt environment, we first determined the drug's cytotoxicity.
We have previously demonstrated that high salt (Δ0.05 M
NaCl) synergized with subminimal IL‑17 (0.1 pg/ml) (16) to
induce a 24% enhanced cell proliferation (4,5,8,22), which
will be referred to as stimulating conditions in our current
communication. Importantly, Na‑MRI based human studies
have revealed that breast tumors accumulate high salt for
yet unknown reasons (6,7). As shown in Fig. 1A, prostratin
induced inhibitory effect on cell proliferation in MCF‑7 breast
cancer cells, however, this cytotoxic effect was higher when
cells were culture in high salt culture environment. Further
data analysis has revealed that (Fig. 1B) the IC50 of prostratin
on MCF‑7 cells under basal culture conditions was 37.4±8.7 µg,
while under high salt stimulating conditions the IC50 was
determined to be 7.3±2.9 µg. This suggests that natural plant
product prostratin has more efficient anti‑tumor activity under
tumor microenvironment conditions similar to real human
cancer patients. We have further verified this cytotoxic effect
on other breast related cell lines. In our current study we have
used four breast cancer cell lines namely, MCF‑7 (ER/PR
double positive), MDA‑MB‑231 (triple negative), BT‑20 (Triple
negative), AU‑565 (Her2 positive); and one non‑malignant
breast epithelial cell line, MCF‑10A. As shown in Fig. 1B,
prostratin has upto seven fold higher cytotoxicity (as determined by low IC50) on breast cancer cells over non‑malignant
cells. Of the four breast cancer cell lines, although statistically
insignificant, prostratin seemed to exert higher effect (as determined by Cmax) on the two highly invasive (metastatic) cell
lines, MDA‑MD‑231 and BT‑20 (Fig. 1B). These data strongly
suggest that prostratin can selectively exert it's effect on breast
tumor with minimal effect on normal breast epithelium.
Prostratin inhibits SIK3 expression and phosphorylation. As
we have previously demonstrated that SIK3 plays a critical role
in mediating high salt induced cancer cell proliferation (8). In
our current study, we studied the potential cytotoxic effect of
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Figure 2. Prostratin inhibits SIK3 expression and phosphorylation in breast cancer cells. (A) Westernblot analysis of SIK3 expression in the total cell lysate
of MCF7 cells. Immunoprecipitate of SIK3 was probed with phosphor‑serine antibody; U/S, represents unstimulated condition, i.e., cells cultured under basal
conditions; S, represent cells cultured under high salt stimulating conditions (Δ0.05 M NaCl+0.1 ng/ml IL‑17); Prostratin treatment concentration was 50 µM;
equi‑volume DMSO was used as vehicle control. (B) SIK3 mRNA transcript expression analysis in MCF‑7 cells performed by quantitative RT‑PCR. (C) SIK3
mRNA transcript expression analysis in five breast cell lines mentioned above following high salt stimulating conditions with and without 50 µM prostratin.
Student‑t‑test performed for statistical analysis; significance taken at P<0.05, represented by astericks (*).

Figure 3. Prostratin inhibits HDAC4 phosphorylation in breast cancer cells. (A) Westernblot analysis of HDAC4 phosphorylation in the total cell lysate of MCF7
cells. (B) ELISA‑based HDAC4 activity analysis performed in MCF‑7 cells under various conditions mentioned above. (C) ELISA‑based HDAC4 activity
analysis performed in five breast cell lines mentioned above following high salt stimulating conditions with and without 50 µM prostratin. Student‑t‑test
performed for statistical analysis; significance taken at P<0.05, represented by astericks (*).

prostratin through inhibition of SIK3. As shown in Fig. 2, prostratin induced a 46% inhibition in the SIK3 mRNA expression
following stimulation with high salt on MCF‑7 cells. Prostratin
was able to exert this SIK3 inhibition on all four breast cancer
cells (MCF‑7, MDA‑MB‑231, BT‑20 and AU‑565). Similar
to evidence from cytotoxicity studies, prostratin exerted
slightly greater inhibition (54% vs. 46% inhibition, P>0.05,
statistically non‑significant) of SIK3 expression in highly
invasive MDA‑MB‑231 and BT‑20, over less invasive MCF‑7
and AU‑565 breast cancer cell lines. Furthermore, along
with reduced SIK3 expression prostratin also inhibited the
phosphorylation of SIK3 suggesting an inhibition of SIK3
mediated downstream signaling.

Prostratin inhibits activation of HDAC4, a SIK3 downstream
element. Previous studies in our laboratory have demonstrated that high salt stimulating conditions induce SIK3
mediated phosphorylation of HDAC4, and siRNA mediated
knock‑down of SIK3 completely abrogated HDAC4 phosphorylation (8). Towards this, as prostratin inhibited SIK3,
we studied the drug effect on HDAC4 phosphorylation, a
SIK3 downstream element. As shown in Fig. 3A, prostratin
inhibited the phosphorylation of HDAC4. Further, ELISA
based biochemical analysis of HDAC4 activity (Fig. 3B)
demonstrated that prostratin treated cell lysate obtained
following treatment with high salt stimulation induced a
50% inhibition of HDAC4 specific substrate conversion.
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Figure 4. Prostratin inhibits CXCR4 expression in breast cancer cells. (A) Flow cytometry based analysis for expression of CXCR4 in MCF7 cells. (B) CXCR4
expression following treatment with SIK3 siRNA and scramble siRNA. ($) represents statistical significance made by comparison between (stimulated+scramble
siRNA) vs. (stimulated+scramble siRNA+50 µM prostratin) samples. (C) CXCR4 expression analysis performed in five breast cell lines mentioned above
following high salt stimulating conditions with and without 50 µM prostratin. Student‑t‑test performed for statistical analysis; significance taken at P<0.05.
(*) represents statistical significance made by comparison between stimulated and stimulated+prostratin samples.

Taken together, these data indicate that prostratin exerts its
anti‑tumor effect through inhibition of SIK3/HDAC4 mediated cell proliferation.
Prostratin downregulates CXCR4 in SIK3 dependent manner.
As our cytotoxicity and SIK3 functional mechanistic data
suggested that prostratin exerted a slightly higher (but
statistically insignificant) inhibitory effect on highly invasive MDA‑MB‑231 and BT‑20 cancer cell lines, we tested if
prostratin could exerted anti‑cancer effect through inhibition
of metastasis. CXCR4 is a well‑established metastatic factor
which is known to promote cancer cell invasion and spreading
to other organs in patients (24). Importantly, prostratin has
previously been demonstrated to inhibit CXCR4 expression
in T‑lymphocytes. Therefore, in the present study we tested if
prostratin inhibited CXCR4 expression in breast cancer cells.
As shown in Fig. 4A, prostratin treatment inhibited the CXCR4
expression (from 72.9±7.9% to 31.4±5.1%; P<0.05) following
high salt stimulation. Prostratin exerted no effect following
siRNA mediated SIK3 knock down, suggesting prostratin
inhibits SIK3 induced CXCR4 metastatic factor expression.
Further, prostratin was able to inhibit CXCR4 in all four breast
cancer cell lines (Fig. 4C) with no effect on non‑malignant
breast epithelial cell line. These data suggest that prostratin is
exerts strong anti‑cancer effect through potential inhibition of
metastasis.
Discussion
The natural product prostratin is extensively researched in
the context of therapy against HIV infection and activation
of CD4+T lymphocytes. However, there is limited evidence
to determine the effect of prostratin on cancer cells. Various
ligand‑drug interaction studies have suggested that prostratin
exerts its anti‑viral effect through the diacylglycerol (DAG)
binding domain of protein kinase C (PKC), leading to PKC
enzymatic activation (11). This logic behind ligand mechanistics of prostratin, a phorbol ester, seems to have to been

inspired from the understanding of another structurally
related phorbol ester, phorbol 12‑myristate 13‑acetate (PHA),
which also stimulates PKC through allosteric activation by
DAG. However, inspite of structural similarity, while PHA is
known to promote tumor growth, prostratin is not considered
to promote tumor growth. Szallasi et al (25) have demonstrated that prostratin was able to inhibit tumor growth in
CD1 murine cutaneous tumor models. However, to‑date
limited literature on the exact cytotoxicity doses of prostratin on cancer cell lines. In our current study we report that
the IC50 of prostratin on four different breast cancer cells
under basal culture conditions was around 35 µM (Fig. 1)
however, upon stimulating culture conditions, mimicking
the real tumor microenvironment, the IC50 was around
7 µM (Fig. 1), thus suggesting that prostratin might have an
anticancer effect under in vivo solid tumor environment in
animal models and humans. Further, it is important to note
that the IC50 of prostratin on non‑malignant breast cells
(MCF‑10A) under basal culture conditions (which is close to
basal physiological conditions within human body) is 73 µM
(Fig. 1). This data strongly suggests that prostratin has a 10
fold higher therapeutic index and therefore could specifically
target malignant cells while being safe on normal cells. This
data could set a stage for future preclinical studies in murine
tumor models to exactly decipher the anticancer effect and
therapeutic dose of prostratin.
To date, extensive research with prostratin as an anti‑viral
drug has demonstrated that the drug exerts its effect through
activation of PKC (11). However, using fibroblast cell lines
stably transfected with H‑Ras and K‑Ras, Wang et al (26)
have demonstrated yet another mechanism for prostratin,
wherein the researchers have demonstrated that prostratin
inhibits K‑Ras/calmodulin interaction and there by inhibiting
the oncogenic potential of their transfected cell lines. This
evidence suggests, in addition to PKC activation, prostratin
could exert its anti‑cancer effect through other signaling
pathways. In the present study as prostratin demonstrated
higher cytotoxicity when cells were cultured under stimulating
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conditions (sub‑minimal IL‑17, 0.1 ng/ml, synergized high
salt, Δ0.05 M NaCl, culture conditions) commonly found
in solid tumors. This data suggest that prostratin might act
through salt‑specific signaling mechanism. Importantly, we
have recently demonstrated that salt‑inducible kinase, SIK3, is
specifically upregulated and mediated proliferative signaling
following high salt stimulating conditions. Therefore, we
tested for the potential effect of prostratin on SIK3 expression. Previous studies from our laboratory have demonstrated
that (8), while IL‑17 induced both mTORC1 and mTORC2
pathways, only mTORC2 is a direct upstream signaling
molecule for SIK3. High salt treatment could directly induce
SIK3 phosphorylation, which is further enhanced following
co‑treatment with subminimal‑IL‑17. These studies clearly
point out that SIK3 is a direct downstream factor for high
salt synergized inflammatory stress. In our current study as
we found prostratin could down‑regulate the activation of
SIK3, we wanted to study under treatment conditions wherein
we had highest stimulation of SIK3 and then quantitatively
analyze for the prostratin inhibition of SIK3. Therefore, as
the focus of the current study is SIK3, to have highest stimulation of SIK3 in our current work, we have used high salt
and sub‑minimal IL‑17 co‑treatment conditions. Our current
studies demonstrate that prostratin inhibits SIK3 expression
and phosphorylation (Fig. 2). Also, the phosphorylation and
activity of histone deacetylase (HDAC4), a direct downstream
molecule of SIK3 (9), was inhibited by prostratin (Fig. 3).
Taken together, these data strongly suggest that prostratin
inhibits SIK3 mediated pro‑cancer signaling. However, more
elaborate studies in the preclinical SIK3 knock‑out animal
models and detailed cell cycle studies would be warranted to
delineate the effect of prostratin on SIK3 mediated signaling
in solid tumors.
Prostratin had been shown to elicit anti‑HIV effect
by inducing down‑regulation of CD4, C‑X‑C chemokine
receptor type 4 (CXCR4), and thereby protecting CD4+T
cells from HIV‑1 entry (12). In acutely infected cells, prostratin is thought to enhance cellular protection possibly due
to cytostatic effects (27). In the context of cancer CXCR4
is well‑known to induce cancer cell migration and metastasis (24). Elevated membrane expression of CXCR4 is
observed in several cancers. Further CXCR4 is positively
correlated with cancer progression and considered a poor
prognostic biomarker (28). Several factors contribute to the
upregulation of CXCR4 in malignant cells. Previous studies
in our laboratory have demonstrated that, under high salt
stimulating conditions, enhanced SIK3 signaling through
MMP‑9 pathway mediates upregulation of CXCR4 membrane
expression (8). In our current studies we demonstrate that
prostratin inhibits CXCR4 expression in breast cancer cell
lines (Fig. 4). Furthermore, siRNA mediated knockdown of
SIK3 under high salt stimulating culture conditions did not
induce expression of CXCR4, thus suggesting that, atleast
that under our experimental conditions, prostratin mediated
CXCR4 inhibition is mediated by the direct drug induced
downregulation of SIK3.
In conclusion, we demonstrated a novel mechanism of
action for prostratin. SIK3 inhibition could be a novel area
of drug‑target anti‑cancer studies. In addition to PKC activation, prostratin could exert its anti‑cancer effect through
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inhibition of SIK3. This data could provide a mechanistic
basis for further research to study the potential application of
prostratin as an add‑on drug to the anti‑cancer chemotherapeutic regimen.
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